← Leaderboards
Barry J Maurer
Avanti Polar Lipids, Inc.
$1,673,802
Attributed
$1,673,802
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $443.6K · FY2005–12$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$1,673,802 · 3
By mechanism
R01$980,276 · 1
R15$443,579 · 1
R41$249,947 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cell Line”
- David Heimbrook · Leidos Biomedical Research, Inc.$236,973,333
- Dennis R. Burton · Scripps Research Institute$203,685,614
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$177,001,772
- John M Lachin · George Washington University$118,672,444
- David M Nathan · Massachusetts Institute Of Technology$118,672,444
- Fred M Gordin · Social And Scientific Systems, Inc.$82,802,056
Research focus
Cell LineCeramidesFenretinideCytotoxicitySphingosineStereoisomerMetabolismLeukemiaMitochondrial MembraneHypoxiaLabelCancer Cell LineCytotoxicDoseInhibitor/AntagonistCessation Of LifeBaseChemotherapyCaspaseAcute LeukemiaCellsCell TypeIn VitroDihydroceramide
Grant awards (7)
Novel L-threo-sphinganines for ceramides-based cancer therapy$443,579
R15 · FY2012 · CA · contact PI
Novel Ceramide-based Chemotherapy for Acute Leukemia$178,044
R01 · FY2007 · CA · contact PI
Novel Ceramide-based Chemotherapy for Acute Leukemia$58,786
R01 · FY2007 · CA · contact PI
Novel Ceramide-based Chemotherapy for Acute Leukemia$243,902
R01 · FY2006 · CA · contact PI
Novel Ceramide-based Chemotherapy for Acute Leukemia$249,772
R01 · FY2005 · CA
Novel Ceramide-based Chemotherapy for Acute Leukemia$249,772
R01 · FY2004 · CA
PPMP as a Ceramide Catabolism Inhibitor for Chemotherapy$249,947
R41 · FY2003 · CA